Personalis Total Current Liabilities 2018-2024 | PSNL

Personalis total current liabilities from 2018 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Personalis Annual Total Current Liabilities
(Millions of US $)
2023 $47
2022 $33
2021 $31
2020 $41
2019 $50
2018 $58
2017 $
Personalis Quarterly Total Current Liabilities
(Millions of US $)
2024-06-30 $34
2024-03-31 $31
2023-12-31 $47
2023-09-30 $32
2023-06-30 $29
2023-03-31 $34
2022-12-31 $33
2022-09-30 $34
2022-06-30 $42
2022-03-31 $40
2021-12-31 $31
2021-09-30 $27
2021-06-30 $34
2021-03-31 $39
2020-12-31 $41
2020-09-30 $36
2020-06-30 $43
2020-03-31 $52
2019-12-31 $50
2019-09-30 $47
2019-06-30 $56
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.261B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00